Organometallics
Communication
Chemler, S. R. Chem. Eur. J. 2012, 18, 1711−1726. (c) Sherman, E. S.;
Fuller, P. H.; Kasi, D.; Chemler, S. R. J. Org. Chem. 2007, 72, 3896−
3905. (d) Miller, Y.; Miao, L.; Hosseini, A. S.; Chemler, S. R. J. Am.
Chem. Soc. 2012, 134, 12149−12156. (e) Zeng, W.; Chemler, S. R. J.
Am. Chem. Soc. 2007, 129, 12948−12949. (f) Fuller, P. H.; Kim, J.-W.;
Chemler, S. R. J. Am. Chem. Soc. 2008, 130, 17638−17639. (g) Bovino,
M. T.; Chemler, S. R. Angew. Chem., Int. Ed. 2012, 51, 3923−3927.
(h) Liwosz, T. W.; Chemler, S. R. J. Am. Chem. Soc. 2012, 134, 2020−
2023. (i) Sequeira, F. C.; Bovino, M. T.; Chipre, A. J.; Chemler, S. R.
Synthesis 2012, 44, 1481−1484.
in principle be even further enhanced. Further reaction
optimization and expansion of the substrate scope are
underway and will be reported in due course.
ASSOCIATED CONTENT
* Supporting Information
■
S
Text and figures giving full experimental details, character-
ization data, and NMR spectra for all new compounds and
chiral HPLC traces for all chiral products. This material is
AUTHOR INFORMATION
Corresponding Author
■
Author Contributions
The manuscript was written through contributions of all
authors. All authors have given approval to the final version of
the manuscript.
Author Contributions
†Both authors contributed equally.
Notes
The authors declare no competing financial interest.
ACKNOWLEDGMENTS
We thank the National Institutes of Health (GM078383) for
support of this work.
■
REFERENCES
■
(1) Reviews: (a) Mueller, T. E.; Hultzsch, K. C.; Yus, M.; Foubelo,
F.; Tada, M. Chem. Rev. 2008, 3795−3892. (b) Zi, G. F. J. Organomet.
Chem. 2011, 696, 68−75. (c) Chemler, S. R. Org. Biomol. Chem. 2009,
7, 3009−3019. (d) Allaud, I.; Collin, J.; Hannedouche, J.; Schulz, E.
Dalton Trans. 2007, 5105−5118. (e) Hultzsch, K. C. Org. Biomol.
Chem. 2005, 3, 1819−1824. Enantioselective hydroamination of 2-
allylanilines: (f) Knight, P. D.; Munslow, I.; O’Shaughnessy, P. N.;
Scott, P. Chem. Commun. 2004, 894−895. (g) Watson, D. A.; Chiu,
M.; Bergman, R. G. Organometallics 2006, 25, 4731−4733. (h) Shen,
X.; Buchwald, S. L. Angew. Chem., Int. Ed. 2010, 49, 564−567.
(2) (a) Temperini, C.; Cecchi, A.; Scozzafava, A.; Supuran, C. T. J.
Med. Chem. 2009, 52, 322−328. (b) Khan, P. M.; Correa, R. G.;
Divlianska, D. B.; Peddibhotla, S.; Sessions, E. H.; Magnuson, G.;
Brown, B.; Suyama, E.; Yuan, H.; Mangravita-Novo, A.; Vicchiarelli,
M.; Su, Y.; Vasile, S.; Smith, L. H.; Diaz, P. W.; Reed, J. C.; Roth, G. P.
ACS Med. Chem. Lett. 2011, 2, 780−785. (c) Yoon, S. J.; Chung, Y. H.;
Lee, M. S.; Choi, D. R.; Lee, J. A.; Lee, H. S.; Yun, H. R.; Lee, D. K.;
Moon, E. Y.; Hwang, H. S.; Choi, C. H.; Jung, S. H.
Arylsulfonylimidazoline derivatives as a antitumor agent. U.S. Patent
5,932,742, Aug. 3, 1999.
(3) (a) Anas, S.; Kagan, H. B. Tetrahedron: Asymmetry 2009, 2193−
2199. (b) Arp, F. O.; Fu, G. C. J. Am. Chem. Soc. 2006, 128, 14264−
14265. (c) Hou, X. L.; Zheng, B. H. Org. Lett. 2009, 111, 1789−1791.
(d) Xiao, Y.-C.; Wang, C.; Yao, Y.; Sun, J.; Chen, Y.-C. Angew. Chem.,
Int. Ed. 2011, 50, 10661−10664. (e) Wang, D.-S.; Chen, Q.-A.; Li, W.;
Yu, C.-B.; Zhou, Y.-G.; Zhang, X. J. Am. Chem. Soc. 2010, 132, 8909−
8911.
(4) Copper-catalyzed hydroaminations: (a) Komeyama, K.;
Morimoto, T.; Takaki, K. Angew. Chem., Int. Ed. 2006, 45, 2938−
2941. (b) Rao, W.; Kothandaraman, P.; Koh, C. B.; Chan, P. W. H.
Adv. Synth. Catal. 2010, 352, 2521−2530. (c) Taylor, J. G.; Whittall,
N.; Hii, K. K. Org. Lett. 2006, 8, 3561−3564. (d) Ohmiya, H.; Moriya,
T.; Sawamura, M. Org. Lett. 2009, 11, 2145−2147. (e) Munro-
Leighton, C.; Delp, S. A.; Alsop, N. M.; Blue, E. D.; Gunnoe, T. B.
Chem. Commun. 2008, 111−113.
(5) (a) Chemler, S. R. J. Organomet. Chem. 2011, 696, 150−158.
(b) Paderes, M. C.; Belding, L.; Fanovic, B.; Dudding, T.; Keister, J. B.;
7822
dx.doi.org/10.1021/om300744m | Organometallics 2012, 31, 7819−7822